Results 21 to 30 of about 3,814,825 (281)
Biomarkers for Antiplatelet Therapies in Acute Ischemic Stroke: A Clinical Review
Frontiers in Neurology, 2021 Stroke is one of the world's leading causes of disability and death. Antiplatelet agents are administered to acute ischemic stroke patients as secondary prevention.
Adel Alhazzani +6 more
doaj +1 more source
NEW ANTIPLATELET DRUGS (PART 1)
Рациональная фармакотерапия в кардиологии, 2016 Antiplatelet agents are a necessary component of modern atherosclerosis therapy. The difficulties of antiplatelet treatment lie in the balance between the necessary therapeutic effect of the drug and the risk of excessive action leading to the bleeding ...
A. B. Sumarokov
doaj +3 more sources
Novel Antiplatelet Agents in Cardiovascular Disease
Journal of Cardiovascular Pharmacology and Therapeutics, 2020 Antiplatelet therapy reduces atherothrombotic risk and has therefore become a cornerstone in the treatment of cardiovascular disease. Aspirin, adenosine diphosphate P2Y12 receptor antagonists, glycoprotein IIb/IIIa inhibitors, and the thrombin receptor ...
M. Tscharre +2 more
semanticscholar +1 more source
Scientific Reports, 2020 For the first time, a series of highly potent natural product inspired substituted (Z)-3-benzylideneisobenzofuran-1(3H)-ones 28a-t, embraced with electron-withdrawing groups (EWG) and electron-donating groups (EDG) at site I and site II, were prepared ...
Bharti Rajesh Kumar Shyamlal +7 more
semanticscholar +1 more source
Antiplatelet agents for preventing pre-eclampsia and its complications.
Cochrane Database of Systematic Reviews, 2019 BACKGROUND Pre-eclampsia is associated with deficient intravascular production of prostacyclin, a vasodilator, and excessive production of thromboxane, a vasoconstrictor and stimulant of platelet aggregation. These observations led to the hypotheses that
L. Duley +4 more
semanticscholar +1 more source
Cochrane Database of Systematic Reviews, 2020 BACKGROUND Stroke is a leading cause of morbidity and mortality worldwide. Antiplatelet agents are considered to be the cornerstone for secondary prevention of stroke, but the role of using multiple antiplatelet agents early after stroke or transient ...
I. Naqvi, A. Kamal, H. Rehman
semanticscholar +1 more source
Frontiers in Cardiovascular Medicine, 2023 Myocardial infarction with non-obstructive coronary arteries (MINOCA) is a heterogeneous group of diseases with different pathological mechanisms, and it is uncertain whether the classical secondary prevention and treatment strategies for myocardial ...
Wenjie Chen +7 more
doaj +1 more source
Acta Biomedica Scientifica, 2017 The literature review provides basic information about cerebral stroke as one of the leading medical and socio-economic problems that caused high levels of mortality and morbidity from stroke, unfavorable disability index. This fact confirms the need for
E. Y. Kitaeva, V. V. Shprakh
doaj +1 more source
Outcomes of trauma patients on chronic antithrombotic therapies in a trauma center in a rural state
Surgery in Practice and Science, 2023 Objective: The number of trauma patients presenting with chronic antithrombotic therapy is on the rise. The risk of hemorrhage, the leading cause of death in trauma patients, increases for those on such therapy.
Benjamin Moore +11 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Alternative approaches to the use of two component antiplatelet therapy in patients with acute coronary syndrome are discussed. Reasons to the development and implementation of new, more powerful antiplatelet agents are considered.
S. R. Gilyarevskiy +3 more
doaj +3 more sources